Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial.
Stephan WillemsKatrin BorofAxel BrandesGuenter BreithardtA John CammHarry J G M CrijnsLars EckardtNele GesslerAndreas GoetteLaurent M HaegeliHein HeidbuchelJosef KautznerGhulam Andre NgRenate B SchnabelAnna SulingLukasz SzumowskiSakis ThemistoclakisPanos VardasIsabelle C van GelderKarl WegscheiderPaulus F KirchhofPublished in: European heart journal (2021)
The clinical benefit of early, systematic rhythm control was not different between asymptomatic and symptomatic patients in EAST-AFNET 4. These results call for a shared decision discussing the benefits of rhythm control therapy in all patients with recently diagnosed AF and concomitant cardiovascular conditions (EAST-AFNET 4; ISRCTN04708680; NCT01288352; EudraCT2010-021258-20).
Keyphrases
- atrial fibrillation
- left atrial
- end stage renal disease
- catheter ablation
- heart rate
- oral anticoagulants
- ejection fraction
- direct oral anticoagulants
- left atrial appendage
- newly diagnosed
- chronic kidney disease
- heart failure
- clinical trial
- prognostic factors
- peritoneal dialysis
- percutaneous coronary intervention
- study protocol
- phase iii
- blood pressure
- patient reported outcomes
- venous thromboembolism
- depressive symptoms
- physical activity
- bone marrow
- sleep quality